Biobot Surgical key facts
as of Oct 2026- Developer of a robotic prostate biopsy and treatment system designed for improved clinical outcomes.
- Biobot Surgical is valued at approximately $54.3M as of Oct 2026 (last reported valuation).
- It has raised $38.7M; the latest was Later Stage VC ($8.5M) in Apr 2026.
- Notable investors include ClavystBio, Andreas Handayanto, Ang Tiam, Astrid Hill Investment, Chia Chee Ming — 16 tracked in total.
- Status: Privately Held (backing).
Biobot Surgical's last reported valuation, Mar 2024. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Biobot Surgical: the Monday email on marks, rounds and moves
Biobot Surgical funding rounds
No funding rounds for Biobot Surgical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Biobot Surgical
16+Biobot Surgical valuation
Biobot Surgical's last reported valuation was $54.3 million in Mar 2024. No priced round, secondary trade or fund mark has surfaced since.
Biobot Surgical investors
16 investors are on record for Biobot Surgical, including ClavystBio, Andreas Handayanto, Ang Tiam and Astrid Hill Investment.
About Biobot Surgical
Developer of a robotic prostate biopsy and treatment system designed for improved clinical outcomes. The company provides complete prostate coverage, aided by robotic targeting and accurate biopsy needle positioning, enabling physicians to detect prostate cancer in patients early and providing confidence to enroll patients in an active surveillance program.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2007
- Employees
- 42
- Website
- biobotsurgical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.